perspective therapeutics inc - CATX

CATX

Close Chg Chg %
4.38 0.01 0.30%

Closed Market

4.39

+0.01 (0.30%)

Volume: 1.05M

Last Updated:

Apr 2, 2026, 3:59 PM EDT

Company Overview: perspective therapeutics inc - CATX

CATX Key Data

Open

$4.24

Day Range

4.22 - 4.56

52 Week Range

1.60 - 6.16

Market Cap

$502.44M

Shares Outstanding

113.93M

Public Float

92.55M

Beta

1.87

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.39

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.62M

 

CATX Performance

1 Week
 
8.35%
 
1 Month
 
-11.27%
 
3 Months
 
58.06%
 
1 Year
 
145.00%
 
5 Years
 
-61.65%
 

CATX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 14
Full Ratings ➔

About perspective therapeutics inc - CATX

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

CATX At a Glance

Perspective Therapeutics, Inc.
2401 Elliott Avenue
Seattle, Washington 98121
Phone 1-206-676-0900 Revenue 884.00K
Industry Medical Specialties Net Income -103,121,000.00
Sector Health Technology Employees 166
Fiscal Year-end 12 / 2026
View SEC Filings

CATX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 229.622
Price to Book Ratio 0.987
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.613
Enterprise Value to Sales 69.572
Total Debt to Enterprise Value 0.053

CATX Efficiency

Revenue/Employee 5,325.301
Income Per Employee -621,210.843
Receivables Turnover 0.851
Total Asset Turnover 0.003

CATX Liquidity

Current Ratio 5.174
Quick Ratio 5.174
Cash Ratio 5.047

CATX Profitability

Gross Margin -267.76
Operating Margin -11,715.385
Pretax Margin -11,813.122
Net Margin -11,665.271
Return on Assets -33.192
Return on Equity -41.646
Return on Total Capital -49.283
Return on Invested Capital -41.18

CATX Capital Structure

Total Debt to Total Equity 1.571
Total Debt to Total Capital 1.547
Total Debt to Total Assets 1.186
Long-Term Debt to Equity 1.243
Long-Term Debt to Total Capital 1.224
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Perspective Therapeutics Inc - CATX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
10.79M 1.43M 1.45M 884.00K
Sales Growth
+7.38% -86.72% +1.39% -39.20%
Cost of Goods Sold (COGS) incl D&A
6.18M 1.02M 2.31M 3.25M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
325.00K 1.02M 2.31M 3.25M
Depreciation
284.00K 981.00K 2.30M 3.24M
Amortization of Intangibles
41.00K 40.00K 7.00K 7.00K
COGS Growth
+25.28% -83.48% +125.86% +40.98%
Gross Income
4.62M 413.00K (852.00K) (2.37M)
Gross Income Growth
-9.86% -91.05% -306.30% -177.82%
Gross Profit Margin
+42.76% +28.80% -58.60% -267.76%
2022 2023 2024 2025 5-year trend
SG&A Expense
12.01M 41.35M 65.94M 101.20M
Research & Development
2.58M 20.33M 39.33M 70.96M
Other SG&A
9.43M 21.02M 26.61M 30.23M
SGA Growth
+40.30% +244.42% +59.46% +53.46%
Other Operating Expense
- - - -
-
Unusual Expense
- - 24.06M 10.00M
-
EBIT after Unusual Expense
(7.39M) (40.94M) (90.86M) (113.56M)
Non Operating Income/Expense
119.00K 919.00K 10.48M 9.51M
Non-Operating Interest Income
119.00K 934.00K 10.52M 8.11M
Equity in Earnings of Affiliates
- (17.00K) (8.00K) (2.00K)
Interest Expense
- 84.00K 48.00K 376.00K
Interest Expense Growth
- - -42.86% +683.33%
-
Gross Interest Expense
- 84.00K 48.00K 376.00K
Interest Capitalized
- - - -
-
Pretax Income
(7.27M) (40.11M) (80.43M) (104.43M)
Pretax Income Growth
-114.70% -451.51% -100.54% -29.84%
Pretax Margin
-67.36% -2,796.79% -5,531.43% -11,813.12%
Income Tax
- (2.65M) (2.10M) (793.00K)
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- (2.65M) (2.10M) (793.00K)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- (17.00K) (8.00K) (2.00K)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(7.27M) (37.45M) (78.33M) (103.64M)
Minority Interest Expense
- - - -
-
Net Income
(7.27M) (37.45M) (78.33M) (103.64M)
Net Income Growth
-114.70% -415.06% -109.13% -32.31%
Net Margin Growth
-67.36% -2,611.92% -5,387.21% -11,723.42%
Extraordinaries & Discontinued Operations
- (9.05M) (949.00K) 514.00K
Discontinued Operations
- (9.05M) (949.00K) 514.00K
Net Income After Extraordinaries
(7.27M) (46.51M) (79.28M) (103.12M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(7.27M) (46.51M) (79.28M) (103.12M)
EPS (Basic)
-0.5122 -1.7377 -1.2306 -1.3971
EPS (Basic) Growth
-56.88% -239.26% +29.18% -13.53%
Basic Shares Outstanding
14.20M 26.76M 64.42M 73.81M
EPS (Diluted)
-0.5122 -1.7377 -1.2306 -1.3971
EPS (Diluted) Growth
-56.88% -239.26% +29.18% -13.53%
Diluted Shares Outstanding
14.20M 26.76M 64.42M 73.81M
EBITDA
(7.07M) (39.92M) (64.49M) (100.31M)
EBITDA Growth
-119.71% -464.96% -61.55% -55.55%
EBITDA Margin
-65.46% -2,783.82% -4,435.42% -11,347.62%

Snapshot

Average Recommendation BUY Average Target Price 12.933
Number of Ratings 14 Current Quarters Estimate -0.27
FY Report Date 06 / 2026 Current Year's Estimate -1.158
Last Quarter’s Earnings -0.29 Median PE on CY Estimate N/A
Year Ago Earnings -1.41 Next Fiscal Year Estimate -1.149
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 14 15 11
Mean Estimate -0.27 -0.28 -1.16 -1.15
High Estimates -0.21 -0.22 -0.86 -0.84
Low Estimate -0.36 -0.37 -1.57 -1.60
Coefficient of Variance -15.54 -15.28 -18.06 -19.26

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 13
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Perspective Therapeutics Inc in the News